%0 Journal Article
%T Pharmaceutical consultation as a tool to improve health outcomes for patients with type 2 diabetes
%A Arnaldo Zubioli
%A Maria Ang¨¦lica Rafaini Covas Pereira da Silva
%A Raquel Soares Tasca
%A Rui Curi
%J Brazilian Journal of Pharmaceutical Sciences
%D 2013
%I Universidade de S?o Paulo
%X This study develops and evaluates a pharmaceutical consultation program (PCP) to improve treatment for Type 2 diabetes patients (T2DP) and reduce risk factors for diabetic complications with possible application in other chronic diseases. We recruited T2DP receiving conventional medical treatment but with fasting glycemia >140mg/dl and/or glycated hemoglobin >7%. The PCP includes strategies obtained from Dader's method, the PWDT (Pharmacist's Workup of Drug Therapy method) model of pharmaceutical care, the SOAP (Subjective data, Objective data, Assessment, and Plan of care) method, and concepts based on a nursing care model. The PCP evaluated lifestyle, pharmacotherapy and monitoring it using laboratory tests, vital signs, and anthropometry. These procedures were repeated every 4 months for 1 year. Data obtained in each consultation were used to provide patient education focusing on healthy lifestyles and medications. Fifty patients completed the PCP. There were reductions in glycemia (P<0.0001), glycated hemoglobin (P=0.0022), cholesterolemia (P=0.0072), triacylglycerolemia (P=0.0204) and blood pressure (P<0.0001). Increased concordance with drug treatment and correction of drug-related problems contributed to improved treatment. We can therefore conclude that our PCP was suitable for improving health outcomes in T2DP by reducing risk factors for diabetic complications. Neste estudo, desenvolvemos e avaliamos um programa de consulta farmac¨ºutica (PCF) visando melhorar o tratamento de pacientes diab¨¦ticos tipo 2 (PDT2) e reduzir os fatores de risco de complica  es diab¨¦ticas com possibilidade de aplica  o em outras doen as cr nicas. Para alcan ar este prop¨®sito, PDT2 recebendo tratamento m¨¦dico convencional, apresentando glicemia de jejum > 140 mg/dl e/ou hemoglobina glicada >7% foram selecionados. O PCF inclui estrat¨¦gias obtidas a partir do m¨¦todo de Dader, do modelo de cuidados farmac¨ºuticos PWDT (Pharmacist's Workup of Drug Therapy method), do m¨¦todo SOAP (Subjective data, Objective data, Assessment, and Plan of care) e conceitos baseados em um modelo de cuidados em enfermagem. O PCF avaliou o estilo de vida, farmacoterapia e seu monitoramento atrav¨¦s de exames laboratoriais, sinais vitais e antropometria. Estes procedimentos foram repetidos a cada 4 meses durante 1 ano. Os dados obtidos em cada consulta possibilitaram oferecer educa  o focada no estilo de vida e uso de medicamentos. Para os 50 pacientes que concluiram o PCF houve redu  o da glicemia (P < 0.0001), hemoglobina glicada (P = 0.0022), colesterolemia (P = 0.0072), triacilgliceridemia (P=
%K Aten  o farmac¨ºutica
%K Diabetes tipo 2
%K Diabetes tipo 2
%K Consulta farmac¨ºutica
%K Hemoglobina glicada
%K Educa  o em diabetes
%K Farm¨¢cia
%K Pharmaceutical care
%K Type 2 diabetes
%K Type 2 diabetes
%K Pharmaceutical consultation
%K Glycated hemoglobin
%K Diabetes education
%K Pharmacy
%U http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502013000100010